INJ consolidates within $4.40–$5.55 recent range amid persistent long-term resistance: weekly forecast

INJ consolidates within $4.40–$5.55 recent range amid persistent long-term resistance: weekly forecast
Injective gains 7.85% this week

Injective (INJ) is currently trading at $4.62, marking a weekly gain of $0.34 or 7.85%. The asset sits above its MA-20 ($3.64), but remains well below both the MA-50 ($7.75) and MA-200 ($12.99), highlighting a short-term recovery amid persistent long-term bearish pressure.

INJ price prediction
24H -12.15%
$4.34
48H -27.94%
$3.56
7D -24.9%
$3.71
1M 43.32%
$7.08
3M 252.23%
$17.4
6M 206.88%
$15.16
12M 177.33%
$13.7
Current price: $ 4.94 -0.69 12.27%
Real-time Data 21:20
Daily range 5 Arrow from to Icon 5.58
Weekly range 4.78 Arrow from to Icon 6.59
Loading...

Highlights

  • INJ price action shows short-term buyer dominance but fails to sustain gains above previous weekly highs.
  • Key technical indicators present conflicting signals, with momentum bearish but short-term oscillators indicating overbought conditions.
  • INJ is expected to consolidate within a $4.40–$5.55 range, with a higher probability of sideways or downward price movement.

Mixed technical outlook as overbought signals clash with persistent selling

Weekly technical analysis on INJ highlights diverging signals. The price holds above MA-20 acting as dynamic support, while the MA-50 and MA-200 overhead signal unresolved longer-term resistance. Support for the week is located near $4.40, with resistance at $5.55. The weekly RSI remains in the sell zone, and although Stochastic RSI and CCI are overbought, momentum readings from MACD and ADX point to ongoing selling pressure. Bull/Bear Power indicators also show overbought conditions, while weekly volatility at 37.61% signals significant price swings.

Injective asset chart
Injective price dynamics. Source: TradingView.

Sideways bias expected as limited upside probability tempers breakout hopes

For the next 7 days, INJ is expected to trade between $4.40 and $5.55, likely consolidating within this range after recent volatility. A bullish scenario would require a sustained breakout above $5.55, potentially triggering renewed upside momentum. However, with none of the four key weekly indicators registering Buy or Strong Buy, an upward move carries less than a 20% probability. The base case anticipates sideways movement, while a break below $4.40 could expose INJ to renewed downside pressure towards longer-term support levels.

Viktoras Karapetjanc, expert at Traders Union, sees compelling short-term interest building in INJ as it achieved a strong 7.85% rise this week and held above the MA-20, despite broad long-term bearish momentum. He believes the current price structure offers clear range-trading opportunities between $4.40 and $5.55, especially given the high weekly volatility of 37.61%. Macro and sentiment drivers remain secondary this week, with technical factors dominating — overbought oscillators and continued selling pressure highlight potential setups for active traders. Karapetjanc remains constructive, expecting consolidation, but acknowledges any breakout above $5.55 could set off significant upside moves. "With buyers regaining control above $4.40, the bullish structure remains intact — I expect this week will offer multiple setups for disciplined range traders."

Earlier, analysts noted that Injective maintained a broadly bullish short-term structure but faced mixed momentum signals amid heightened volatility. The current setup reinforces those cautionary signals, with a potential consolidation phase ahead and increased significance on the $4.40 support level as a trigger for renewed downside risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.